logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Sanofi and Regeneron: Remarkable Results from Libtayo's Trial on Patients with Advanced Non-Small Cell Lung Cancer

Sanofi and Regeneron: Results from Libtayo® Trial Sanofi ( SNY ) and Regeneron ( REGN ) announced that the primary endpoint of overall survival ( OS ) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo®  (cemiplimab)...

Read More

April 27, 2020

0

Amgen and UCB product for bone fracture in susceptible postmenopausal women. What about the Market's deep dips?

Another reason was found to hit the market when the economy is good and sustained and expected to be of a long duration. Of a short duration are the causes presented as economy killers. They are almost all related to...

Read More

December 6, 2018

0

Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ ( NKTR ) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology ( ASH ) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson...

Read More

December 11, 2019

0

The FDA Cleared Moderna's Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

Moderna Coronavirus Vaccine Cleared for Phase 2 Moderna ( MRNA ) provided business updates for the first quarter of 2020 and highlighted pipeline progress. The current most important of the news is that the FDA has cleared Moderna’s coronavirus vaccine to...

Read More

May 7, 2020

0

Ionis and Alnylam Secured Their Future Prosperity

Ionis Pharmaceuticals Ionis Pharmaceuticals ( IONS ) announces a private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024. To read this news go to the original  content to download multimedia by clicking here .  During...

Read More

December 12, 2019

0

There are no reasons for the Market's tumbling. The value of the Biotech Revolution.

Today, the market took another beating as a result of either an intentional or an unintentional lack of clearance by professionals in describing correctly the standing of employment and other current economic realities. They pinpointed irrelevant reasons in an effort to...

Read More

December 7, 2018

0

Marinus Pharmaceuticals: A successful treatment for Postpartum Depression

Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV),  the Magnolia Study, and oral dose, the Amaryllis Study, in women with postpartum depression (PPD) . Based on the positive results, the company is...

Read More

December 10, 2018

0

Amarin: The FDA Approves Vascepa for Lowering Cardiovascular Risk

From Amarin Amarin ( AMRN )  announced the U.S. FDA has approved a new indication and label expansion for Vascepa®  (icosapent ethyl) capsules. According to Amarin’s press release, with this label expansion approval, Vascepa has become the first and only FDA...

Read More

December 16, 2019

0

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

Regenxbio Results from RGX-121 for MPSII Regenxbio ( RGNX ) announced interim data from Phase I/II trial of RGX-121 for Mucopolysaccharidosis Type II ( MPS II) . RGX-121  is designed to deliver the gene that encodes iduronate-2-sulfatase ( I2S )...

Read More

December 19, 2019

0

More fom the Prohost Portfolio

More from the Prohost Portfolio with Our Observations Gilead ( GILD ) has cash and new products reaching the market, and its agreement with Galapagos will soon bring another drug approval. We will tackle Gilead’s news and all the firms...

Read More

December 20, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 87
  • 88
  • 89
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy